摘要
(1)目的采用尾静脉注射制备小鼠红白血病模型,探讨α-半乳糖苷神经酰胺(α-Galcer)对红白血病发生和发展的影响。(2)方法体外培养小鼠红白血病细胞系FBL-3,经尾静脉注射接种C57BL/6小鼠。将FBL-3接种小鼠进一步分为α-Galcer处理组和溶剂对照处理组,于FBL-3接种当天分别注射α-Galcer和溶剂DMSO.观察不同处理组FBL-3细胞接种小鼠总体变化,并于FBL-3接种后第8周处死小鼠,观察外周血血象变化和肿瘤结节形成情况。(3)结果与正常小鼠相比,FBL-3细胞接种小鼠实验期间皮肤感染增加。外周血有核红细胞增加,并且出现明显的实体器官肿瘤结节,而α-Galcer处理显著抑制实体器官肿瘤结节的形成。(4)结论通过FBL-3细胞尾静脉注射初步建立红白血病肿瘤小鼠模型,α-Galcer处理对小鼠白血病的发展发挥抑制作用。
Objective To prepare erythroleukemia mouse model through tail vein injection of FBL-3cell and investigate the effect ofα-Galcer on the occurrence and development of erythroleukemia.Methods FBL-3erythroleukemia cells were cultured in vitro and C57BL/6erythroleukemia mouse models were prepared by tail vein injection of FBL-3cells.The FBL-3injected mice were further divided into two groups by injectingα-Galcerand solvent DMSO respectively on the date of FBL-3injection.The overall changes of FBL-3injected mice in each group were observed during this experiment.8weeks after FBL-3injection,the FBL-3injected mice were killed and peripheral blood and tumor nodules formation were detected.Results Compared with normal C57BL/6 mice,the FBL-3injected mice demonstrated obvious skin infection,increased nucleated red blood cells and apparent tumor nodules formation,whileα-Galcer treatment significantly inhibited the formation of tumor nodules on solid organs.Conclusion Erythroleukemia mouse models were prepared preliminarily by tail intravenous injection of FBL-3cells,andα-Galcer treatment exhibited an inhibitory effect on the development of leukemia in mice.
引文
[1]李娟,郑全辉.NKT细胞研究进展[J].中国免疫学杂志,2015,31(5):700-703
[2]Faith C,Robertson,Jay A,et al.NKT Cell Networks in the Regulation of Tumor Immunity[J].Front Immunol,2014,5:543
[3]田雨,王娜,宋天姣,等.NKT细胞激活剂α-Galcer对小鼠肺肿瘤细胞生长的影响[J].华北理工大学学报(医学版),2016,4(18):323-325
[4]郑全辉,张爱红,郑爱华,等.MiR-150缺失增强小鼠NKT细胞IFN-γ产生并抑制黑色素瘤细胞的肺转移[J].生物化学与生物物理进展,2013,40(5):454-460
[5]庄万传,李秀梅,朱贵华,等.以髓外浸润为首发表现的急性髓系白血病15例[J].白血病.淋巴瘤,2014,5(2):117-119
[6]Zhou J,Li YN,Song YP,et al.Establishment of an erythroleukemia model in CB6F1 mice by transplant with haploidentical mouse leukemic cell line FBL-3[J].Zhongguo Shi Yan Xue Ye Xue Za Zhi,2010,18(5):1128-1131
[7]Weinkove R,Brooks CR,Carter JM,et al.Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia:implications for immunotherapy[J].Haematologica,2013,98(3):376-384